Bremelanotide (PT-141)

Product Name: Bremelanotide (PT-141) Synonyms: N-Acetyl-L-norleucyl-L-alpha-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysine (2-7)-lactam Cas No.: 189691-06-3 Molecular Formula: C50H68N14O10 Molecular Weight: 1025.16 Appearance : white powder Details: Absrtact Bremelanotide (formerly PT-141) is a compound under drug development by Palatin Technologies as a treatment for female sexual dysfunction, hemorrhagic shock and reperfusion injury.

It functions by activating the melanocortin receptors MC1R and MC4R, to modulate inflammation and limitingischemia. It was originally tested for intranasal administration in treating female sexual dysfunctionbut this application was temporarily discontinued in 2008 after concerns were raised over adverse side effects of increased blood pressure.

As of March, 2012, Palatin is conducting a human Phase 2B study using a new subcutaneous drug delivery system that appears to have little effect on blood pressure.